Three-dimensional histologic validation of high-resolution spect of antibody distributions within xenografts

Journal of Nuclear Medicine

Volumn 55, Issue 5, 2014, Pages 830-837

  Branderhorst, Woutjan ^a,c   Blezer, Erwin L A ^a   Houtkamp, Mischa ^d   Ramakers, Ruud M ^b,e,f   Van Den Brakel, Jeroen H ^d   Witteveen, Henry ^d   Van Der Have, Frans ^e,f   Van Andel, Hugo A Gratama ^f   Vastenhouw, Brendan ^e,f   Wu, Chao ^e,f   Stigter vanWalsum, Marijke ^g   Van Dongen, Guus A M S ^g   Viergever, Max A ^a   Bleeker, Wim K ^d   Beekman, Freek J ^e,f  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d GENMAB   (Netherlands)

^e DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

^f MILabs BV   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Antibody; EGFr; Histology; Micro SPECT; Zalutumumab

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; INDIUM 111; TRACER; ZALUTUMUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE QUALITY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; ISOTOPE LABELING; MOLECULAR IMAGING; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RADIATION DOSE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THREE DIMENSIONAL IMAGING; TUMOR XENOGRAFT; UPREGULATION; VALIDATION PROCESS;

ANTIBODY; EGFR; HISTOLOGY; MICRO-SPECT; ZALUTUMUMAB;

ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMAGING, THREE-DIMENSIONAL; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84901375009     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.125401     Document Type: Article

References (39)

1. Brindle K. New approaches for imaging tumour responses to treatment. Nat Rev Cancer. 2008;8:94-107.
2. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23:1147-1157.
3. Van Dongen GAMS, Visser GWM, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. Oncologist. 2007;12:1379-1389.
4. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23:1137-1146.
5. Das M, Mohanty C, Sahoo SK. Ligand-based targeted therapy for cancer tissue. Expert Opin Drug Deliv. 2009;6:285-304.
6. Machiels J-P, Subramanian S, Ruzsa A, et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol. 2011; 12:333-343.
7. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59:21-26.
8. Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol. 2008; 47:9-19.
9. Lammerts van Bueren JJ, Bleeker WK, Bøgh HO, et al. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res. 2006;66:7630-7638.
10. Basu S, Kwee TC, Gatenby R, Saboury B, Torigian DA, Alavi A. Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging. 2011;38:987-991.
11. Goorden MC, van der Have F, Kreuger R, et al. VECTor: a preclinical imaging system for simultaneous submillimeter SPECTand PET. J Nucl Med. 2013;54:306-312.
12. Van der Have F, Vastenhouw B, Ramakers RM, et al. U-SPECT-II: an ultra-highresolution device for molecular small-animal imaging. J Nucl Med. 2009;50:599-605.
13. Wu C, Have F, Vastenhouw B, Dierckx RAJO, Paans AMJ, Beekman FJ. Absolute quantitative total-body small-animal SPECT with focusing pinholes. Eur J Nucl Med Mol Imaging. 2010;37:2127-2135.
14. Wu C, de Jong JR, Gratama van Andel HA, et al. Quantitative multi-pinhole small-animal SPECT: uniform versus non-uniform Chang attenuation correction. Phys Med Biol. 2011;56:N183-N193.
15. Chen C-L, Wang Y, Lee JJS, Tsui BMW. Toward quantitative small animal pinhole SPECT: assessment of quantitation accuracy prior to image compensations. Mol Imaging Biol. 2009;11:195-203.
16. Hoeben BAW, Molkenboer-Kuenen JDM, Oyen WJG, et al. Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a headand-neck squamous cell carcinoma model. Int J Cancer. 2011;129:870-878.
17. Heskamp S, van Laarhoven HWM, Molkenboer-Kuenen JDM, et al. Immuno-SPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. J Nucl Med. 2010;51:1565-1572.
18. Penheiter AR, Griesmann GE, Federspiel MJ, Dingli D, Russell SJ, Carlson SK. Pinhole micro-SPECT/CT for noninvasive monitoring and quantitation of oncolytic virus dispersion and percent infection in solid tumors. Gene Ther. 2012;19:279-287.
19. Umeda IO, Tani K, Tsuda K, et al. High resolution SPECT imaging for visualization of intratumoral heterogeneity using a SPECT/CT scanner dedicated for small animal imaging. Ann Nucl Med. 2012;26:67-76.
20. Zhou Y, Shao G, Liu S. Monitoring breast tumor lung metastasis by U-SPECT-II/CT with an integrin avb3-targeted radiotracer 99mTc-3P-RGD(2). Theranostics. 2012;2:577-588.
21. Shao G, Zhou Y, Wang F, Liu S. Monitoring glioma growth and tumor necrosis with the U-SPECT-II/CT scanner by targeting integrin avb3. Mol Imaging. 2013;12:39-48.
22. Deleye S, Van Holen R, Verhaeghe J, Vandenberghe S, Stroobants S, Staelens S. Performance evaluation of small-animal multipinhole mSPECT scanners for mouse imaging. Eur J Nucl Med Mol Imaging. 2013;40:744-758.
23. Bleeker WK, Lammerts van Bueren JJ, van Ojik HH, et al. Dual mode of action of a human anti-epidermal growth factor receptor monoclonal antibody for cancer therapy. J Immunol. 2004;173:4699-4707.
24. Perk LR, Visser GWM, Vosjan MJWD, et al. 89Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals 90Y and 177Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. J Nucl Med. 2005;46:1898-1906.
25. Masui H, Moroyama T, Mendelsohn J. Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes. Cancer Res. 1986;46:5592-5598.
26. Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol. 1989;24:148-154.
27. Branderhorst W, Vastenhouw B, van der Have F, Blezer ELA, Bleeker WK, Beekman FJ. Targeted multi-pinhole SPECT. Eur J Nucl Med Mol Imaging. 2011;38:552-561.
28. Branderhorst W, Vastenhouw B, Beekman FJ. Pixel-based subsets for rapid multi-pinhole SPECT reconstruction. Phys Med Biol. 2010;55:2023-2034.
29. Thévenaz P, Ruttimann UE, Unser M. A pyramid approach to subpixel registration based on intensity. IEEE Trans Image Process. 1998;7:27-41.
30. Klein S, Staring M, Murphy K, Viergever MA, Pluim JPW. Elastix: a toolbox for intensity-based medical image registration. IEEE Trans Med Imaging. 2010;29:196-205.
31. Senekowitsch-Schmidtke R, Steiner K, Haunschild J, Möllenstädt S, Truckenbrodt R. In vivo evaluation of epidermal growth factor (EGF) receptor density on human tumor xenografts using radiolabeled EGF and anti-(EGF receptor) mAb 425. Cancer Immunol Immunother. 1996;42:108-114.
32. Ivashchenko O, van der Have F, Villena J, Beekman FJ. Quarter millimeter resolution pre-clinical SPECT with quarter-mm pinholes. Presented at: Annual Congress of the European Association of Nuclear Medicine, October 19-23, 2013, Lyon, France.
33. Mattes MJ, Griffiths GL, Diril H, Goldenberg DM, Ong GL, Shih LB. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells. Cancer. 1994;73:787-793.
34. Press OW, Shan D, Howell-Clark J, et al. Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res. 1996;56:2123-2129.
35. Groen HC, van Walsum T, Rozie S, et al. Three-dimensional registration of histology of human atherosclerotic carotid plaques to in-vivo imaging. J Biomech. 2010;43:2087-2092.
36. Huang L, Gainkam LOT, Caveliers V, et al. SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression. Mol Imaging Biol. 2008;10:167-175.
37. Aerts HJWL, Dubois L, Perk L, et al. Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med. 2009;50:123-131.
38. Cai W, Chen K, He L, Cao Q, Koong A, Chen X. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody. Eur J Nucl Med Mol Imaging. 2007;34:850-858.
39. Niu G, Sun X, Cao Q, et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res. 2010;16:2095-2105.